{"url_path":"/sec/bctx/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-026953-index.html","accession_number":"0001493152-26-026953","cik":"0001610820","ticker":"BCTX","issuer_name":"BriaCell Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-026953-index.html","primary_entity_key":"0001610820","primary_entity_name":"BriaCell Therapeutics Corp."},"word_count":114,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\n**Exhibit\nNo.**\n** **\n**Description**\n\n \n \n \n\n4.1\n \n[Form of Placement Agent Warrant](ex4-1.htm)\n\n \n \n \n\n5.1\n \n[Opinion of Bennett Jones LLP](ex5-1.htm)\n\n \n \n \n\n10.1\n \n[Placement Agency Agreement](ex10-1.htm)\n\n \n \n \n\n23.1\n \n[Consent of Bennett Jones LLP (included in Exhibit 5.1)](ex5-1.htm)\n\n \n \n \n\n99.1\n \n[Pricing Press Release dated May 31, 2026](ex99-1.htm)\n\n \n \n \n\n99.2\n \n[Closing Press Release dated June 2, 2026](ex99-2.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nBRIACELL\nTHERAPEUTICS CORP.\n\n \n \n\n \n*/s/\nWilliam V. Williams*\n\nJune\n2, 2026\nWilliam\nV. Williams\n\n \nPresident\nand Chief Executive Officer"}